Hosted by Nucleus RadioPharma + Facet Life Sciences

The radiopharmaceutical landscape is evolving rapidly—and with it, the complexity of turning early-stage discoveries into FDA-ready products that scale.

Hear from experts from Nucleus RadioPharma and Facet Life Sciences for a dynamic, practical conversation that explores the journey through Chemistry, Manufacturing, and Controls (CMC) from early R&D to IND submission and commercialization.

This webinar is for radiopharma innovators who want to avoid common missteps and better align internal strategy with external partners.

What you’ll learn:

• What to expect from your CDMO and regulatory partners at each development phase


• Why treating GMP as a “ramp” (not isolated steps) is essential for IND-readiness


• Where teams most often underestimate the complexity of CMC


• How to navigate U.S. regulatory pathways, including for global developers entering the market

• Kathy Spencer-Pike – Nucleus RadioPharma


• Chad Crookshanks – Nucleus RadioPharma


• Jamie Chambers – Facet Life Sciences